Answer
In clinical studies of avapritinib for unresectable or metastatic GIST at starting doses of 300 or 400 mg, nausea was very common, occurring in 45.1% of patients overall and at grade ≥3 in 1.5%.
Sources for this answer
- AYVAKYT 300 mg film-coated tabletsBlueprint Medicines (Netherlands) B.V. · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked